Vaccine effectiveness estimated at 82 percent for those aged 16 to 64 years, 60 percent for those aged 65 years or older
Vaccine Effectiveness Lower for Teens With Predominant Omicron
VE increased for adolescents aged 16 to 17 years at seven or more days after a third booster dose during omicron predominance
Homologous Pfizer-BioNTech Booster Safe for Adolescents
Reactions to booster occur with similar frequency as after receipt of second vaccine dose, generally mild to moderate
White House Unveils New COVID-19 Response Strategy
Program to boost research into ‘long COVID’ has also been announced
U.S. NIH Ranks COVID-19 Treatments
The U.S. NIH’s COVID-19 Treatment Guidelines Panel today announced a change to its previous recommendations for COVID-19 treatments.
The purpose of this new NIH statement is to provide clinicians with guidance on the role of bebtelovimab a U.S. FDA Authorized monoclonal antibody treatment, as an additional option for this patient population.
Newly Diagnosed Diabetes at COVID-19 Admission Profiled
Lower levels of glucose and HbA1c, higher levels of inflammatory markers seen in COVID-19 patients with NDDM versus preexisting diabetes
MIS-C Rare in 12- to 20-Year-Olds After COVID-19 Vaccination
Reporting rate was 1.0 case per million vaccinated individuals and 0.3 cases among those without evidence of SARS-CoV-2 infection
CDC Estimates U.S. COVID-19 Infections Now Close to 140 Million
New findings are from the CDC national antibody seroprevalence survey of antibodies to the coronavirus triggered by infection, not by vaccination
Biden Unveils New ‘Test to Treat’ Plan as Key Part of New COVID-19 Strategy
New testing initiative would provide Americans with new antiviral medications as soon as they learn they are infected
Biden Extends FEMA COVID-19 Aid to States
Funding supports FEMA-backed efforts such as vaccination clinics, mass testing sites